Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE vs COLYTE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Sodium picosulfate is a stimulant laxative that is hydrolyzed by colonic bacteria to the active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane, which stimulates colonic peristalsis by acting on the colonic mucosa and inhibiting water and electrolyte absorption. Magnesium oxide acts as an osmotic laxative by drawing water into the intestinal lumen. Citric acid reacts with magnesium oxide to form magnesium citrate, an osmotic laxative.
Colyte is a polyethylene glycol (PEG)-based osmotic laxative that induces diarrhea by retaining water in the gastrointestinal tract via osmotic forces, thereby cleansing the colon.
Bowel cleansing prior to colonoscopy,FDA-approved for bowel preparation in adults
Bowel preparation prior to colonoscopy,Bowel preparation prior to barium enema,Bowel preparation prior to colorectal surgery
Adult: 10 mg oral sodium picosulfate (as 10 mg powder for oral solution) plus 3.5 g magnesium oxide and 12 g citric acid, taken as a single dose the day before colonoscopy, followed by a second dose the next morning, for a total of 2 doses.
4 L oral solution administered as a single dose at a rate of 240 m L every 10 minutes until complete.
The terminal elimination half-life of the active metabolite BHPM is approximately 7-9 hours; clinical effect (bowel cleansing) begins within 1-3 hours and is complete by 6 hours.
Not applicable; systemic absorption is negligible (<0.06%), so a terminal elimination half-life is clinically irrelevant. The gastrointestinal transit time for the solution is approximately 1-3 hours.
Sodium picosulfate is hydrolyzed by colonic bacteria to its active metabolite. Magnesium and citrate are not metabolized; they are absorbed and excreted renally.
Polyethylene glycol is not significantly metabolized and is excreted largely unchanged in feces.
Sodium picosulfate is primarily excreted in feces (90-95%) as the active metabolite BHPM via biliary elimination; <5% excreted renally. Magnesium oxide is excreted renally as magnesium ions. Citric acid is metabolized to bicarbonate and excreted renally.
COLYTE (polyethylene glycol 3350 and electrolytes) is minimally absorbed; <0.1% of the dose is excreted renally. The majority is eliminated unchanged in feces via the gastrointestinal tract, with fecal excretion accounting for >99%.
Sodium picosulfate and its active metabolite BHPM are minimally protein bound (<5%); magnesium oxide and citric acid are not significantly protein bound.
Not applicable; negligible systemic absorption, so protein binding is clinically irrelevant.
The volume of distribution of the active metabolite BHPM is not well defined; magnesium distributes mainly to extracellular fluid (0.2-0.4 L/kg).
Not applicable; negligible systemic absorption, so volume of distribution is clinically irrelevant.
Sodium picosulfate is a prodrug; systemic bioavailability of BHPM after oral administration is approximately 10-15% due to extensive presystemic metabolism.
Oral: <0.1% (systemic bioavailability is negligible due to minimal absorption of polyethylene glycol).
Contraindicated in patients with severe renal impairment (e GFR < 30 m L/min/1.73 m²). For e GFR 30-60, use with caution and ensure adequate hydration.
No dose adjustment required for renal impairment; use with caution in severe renal insufficiency (Cr Cl <30 m L/min) due to potential electrolyte imbalance.
No specific adjustment provided; use with caution in severe hepatic impairment (Child-Pugh C) due to potential for electrolyte disturbances.
No specific dose adjustments for hepatic impairment; use with caution in severe hepatic disease.
Safety and efficacy not established in pediatric patients; not recommended for use in children.
Pediatric patients (≥6 months): 25-40 m L/kg/hour orally or via nasogastric tube until rectal effluent is clear; maximum 4 L.
No specific dose adjustment; ensure adequate hydration and monitor electrolyte levels due to increased risk of renal impairment and dehydration.
No specific dose adjustment; monitor for dehydration and electrolyte disturbances due to reduced renal reserve.
Risk of acute phosphate nephropathy and renal failure, particularly in patients at increased risk (e.g., renal impairment, dehydration, medications affecting renal function).
None
Do not use in patients with gastrointestinal obstruction, perforation, or ileus.,Use caution in patients with renal impairment, electrolyte abnormalities, or those taking medications that affect electrolyte balance.,Monitor for fluid and electrolyte disturbances.,Avoid use in patients with known hypersensitivity to any component.
Risk of electrolyte disturbances (especially in patients with renal impairment or those taking medications affecting electrolytes), aspiration risk (use with caution in patients with impaired gag reflex or at risk of regurgitation), serious fluid and electrolyte abnormalities, cardiac arrhythmias, seizures, and serious adverse reactions including ischemic colitis and ulcerative colitis. Use with caution in patients with severe ulcerative colitis, toxic megacolon, or gastrointestinal obstruction.
Gastrointestinal obstruction, ileus, or perforation,Renal failure (creatinine clearance < 30 m L/min),Ascites,Congestive heart failure (NYHA class III or IV),Known hypersensitivity to any component
Gastrointestinal obstruction, bowel perforation, toxic megacolon, gastric retention, ileus, known hypersensitivity to any component of the product.
Avoid solid food during bowel preparation. Consume only clear liquids (water, clear broth, apple juice, clear gelatin, black coffee or tea without milk, sports drinks). Avoid red, purple, or orange liquids that can be mistaken for blood during colonoscopy. Do not consume alcohol or dairy products.
Avoid all solid foods during bowel preparation; only clear liquids (e.g., water, clear broth, apple juice, black coffee, clear soda) are permitted. Dairy products, red or purple liquids (which can mimic blood), and alcohol should be avoided. Resume a normal diet only after the procedure.
No adequate studies in pregnant women. In animal studies, sodium picosulfate showed no teratogenic effects at clinically relevant doses. Theoretical risk of electrolyte disturbances from magnesium absorption may affect fetal development; avoid in first trimester if possible. Insufficient data for second and third trimesters; use only if clearly needed.
Category C. No adequate and well-controlled studies in pregnant women. Animal studies have not been conducted. Should be used during pregnancy only if clearly needed. Potential for fetal harm due to maternal dehydration or electrolyte imbalance.
Unknown if components excreted in human milk. Sodium picosulfate may be excreted in small amounts; magnesium and citrate are normal milk constituents. Risk to infant considered low with single doses, but caution advised with chronic use. M/P ratio not available.
Not known if excreted in human milk. M/P ratio not determined. Caution advised due to potential for diarrhea in nursing infant. Use only if clearly needed.
No pharmacokinetic studies in pregnancy suggest dose adjustment. Use lowest effective dose and shortest duration. Avoid chronic use due to risk of electrolyte imbalances. Single-dose bowel preparation typical; no adjustment recommended.
No specific dose adjustments recommended. Pharmacokinetic changes in pregnancy not studied; standard bowel preparation dosing should be used with caution due to increased risk of fluid and electrolyte shifts.
Ensure adequate hydration to prevent electrolyte disturbances. Monitor renal function and serum electrolytes, especially in elderly or patients with renal impairment. Administer as a split-dose regimen for optimal bowel cleansing. Avoid use in patients with gastrointestinal obstruction, perforation, or severe inflammatory bowel disease.
Colyte (PEG-3350 with electrolytes) is used for bowel cleansing prior to colonoscopy. Ensure adequate hydration to prevent electrolyte imbalances. Administer in divided doses; split-dose regimen improves tolerability and cleansing quality. Contraindicated in GI obstruction, gastric retention, bowel perforation, toxic colitis, or megacolon. Monitor for bloating, nausea, and vomiting; slow rate if symptoms occur.
Take this medication exactly as prescribed to prepare your colon for a procedure.,Drink plenty of clear liquids before, during, and after taking this medication to prevent dehydration.,You may experience bloating, cramping, or nausea; these are common and usually resolve after the bowel movement begins.,Do not take any other laxatives or stool softeners while using this product unless directed by your doctor.,Stop taking and contact your doctor if you experience severe abdominal pain, vomiting, or signs of an allergic reaction (rash, itching, swelling).,This medication will cause frequent, watery bowel movements; stay near a bathroom.
Follow the prescribed dosing schedule exactly; do not skip doses.,Drink the entire solution as directed, typically with a split-dose regimen (half the evening before, half the morning of the procedure).,Stay well-hydrated; drink clear liquids after starting the preparation.,Avoid solid foods; only clear liquids are allowed until after the procedure.,Expect frequent, watery bowel movements; this is necessary for cleansing.,Notify your doctor if you experience severe bloating, vomiting, or signs of dehydration.,Do not take other medications within 1 hour of starting the preparation.
"Amphetamine increases renal tubular pH, which reduces the excretion rate of magnesium oxide, potentially leading to elevated serum magnesium levels. This interaction may result in hypermagnesemia, manifesting as hypotension, respiratory depression, or cardiac arrhythmias, particularly in patients with renal impairment."
"Mesoridazine, a phenothiazine antipsychotic, can chelate with magnesium ions in the gastrointestinal tract, forming insoluble complexes that reduce the absorption of magnesium oxide. This leads to diminished serum magnesium concentrations, potentially compromising magnesium's therapeutic effects for conditions such as hypomagnesemia or constipation. Clinically, patients may experience inadequate magnesium supplementation, risking exacerbation of electrolyte imbalances or reduced efficacy of magnesium-based therapies."
"Coadministration of magnesium oxide with rosuvastatin may decrease the serum concentration of rosuvastatin, potentially reducing its cholesterol-lowering efficacy. This interaction is thought to be due to chelation of the statin by magnesium ions in the gastrointestinal tract, impairing absorption. Clinically, this may lead to suboptimal lipid control and increased cardiovascular risk."
No interactions on record
Common clinical questions about CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE vs COLYTE, answered by our medical review team.
CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE is a Laxative (Osmotic/Stimulant Combination) that works by Sodium picosulfate is a stimulant laxative that is hydrolyzed by colonic bacteria to the active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane, which stimulates colonic peristalsis by acting on the colonic mucosa and inhibiting water and electrolyte absorption. Magnesium oxide acts as an osmotic laxative by drawing water into the intestinal lumen. Citric acid reacts with magnesium oxide to form magnesium citrate, an osmotic laxative.. COLYTE is a Osmotic Laxative that works by Colyte is a polyethylene glycol (PEG)-based osmotic laxative that induces diarrhea by retaining water in the gastrointestinal tract via osmotic forces, thereby cleansing the colon.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE and COLYTE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE is: Adult: 10 mg oral sodium picosulfate (as 10 mg powder for oral solution) plus 3.5 g magnesium oxide and 12 g citric acid, taken as a single dose the day before colonoscopy, followed by a second dose the next morning, for a total of 2 doses.. The standard adult dose of COLYTE is: 4 L oral solution administered as a single dose at a rate of 240 m L every 10 minutes until complete.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE and COLYTE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE is classified as Category C. No adequate studies in pregnant women. In animal studies, sodium picosulfate showed no teratogenic effects at clinically relevant doses. Theoretical risk of electrolyte disturbance. COLYTE is classified as Category C. Category C. No adequate and well-controlled studies in pregnant women. Animal studies have not been conducted. Should be used during pregnancy only if clearly needed. Potential for. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.